Quick answer: Omega-3 fatty acids EPA and DHA are the most extensively studied anti-inflammatory nutrients, with over 3,000 published trials. The optimal therapeutic dose for anti-inflammatory effect is 2-4g/day of combined EPA+DHA — not total fish oil, which is only 30% EPA+DHA in standard formulations. The REDUCE-IT trial demonstrated 4g/day icosapentaenoic acid (EPA-only, as icosapent ethyl/Vascepa) reduced major cardiovascular events by 25% on top of statin therapy in patients with elevated triglycerides. Omega-3 index (EPA+DHA as percentage of red blood cell fatty acids) above 8% is the biomarker target — below 4% is high-risk and is present in over 70% of American adults. This comprehensive guide covers therapeutic dosing, formulation selection, omega-3 index testing, and evidence-based applications from cardiovascular risk to depression to inflammation resolution.
EPA vs. DHA: Different Molecules, Different Functions
EPA (eicosapentaenoic acid, 20:5 n-3) and DHA (docosahexaenoic acid, 22:6 n-3) are the two long-chain omega-3 fatty acids with the most clinical evidence. They are structurally distinct and have different biological roles — a distinction that matters for clinical applications.
EPA is primarily anti-inflammatory through competition with arachidonic acid (AA, omega-6) for cyclooxygenase and lipoxygenase enzymes, reducing production of pro-inflammatory eicosanoids (PGE2, LTB4) and producing the less inflammatory EPA-derived eicosanoids (PGE3, LTB5). EPA also produces specialized pro-resolving mediators — resolvins (particularly E-series resolvins like resolvin E1) and protectins — that actively resolve inflammation rather than simply suppressing it. EPA is the dominant cardiovascular and systemic anti-inflammatory omega-3. EPA freely distributes to cell membranes throughout the body except the brain.
DHA is the dominant structural fatty acid of the brain and central nervous system — comprising approximately 40% of all polyunsaturated fatty acids in the brain and 60% in the retina. DHA supports neuronal membrane fluidity, synaptic function, and neuroprotection. DHA produces D-series resolvins and neuroprotectins (neuroprotectin D1/protectin D1) that are particularly active in neural tissue inflammation resolution. DHA is preferentially concentrated in the brain and eye; it does not increase triglycerides as effectively as EPA (which makes it less relevant for hypertriglyceridemia treatment). Cognitive benefits and neuroprotection are primarily attributed to DHA.
ALA (alpha-linolenic acid, 18:3 n-3) from plant sources — flaxseed, chia seeds, walnuts, hemp — is NOT equivalent to EPA or DHA. Conversion of ALA to EPA and DHA is extremely inefficient: approximately 0-5% of ALA converts to EPA and less than 0.5% converts to DHA in humans. This conversion is further impaired by high omega-6 intake (which competes for delta-6 desaturase), zinc deficiency, B6 deficiency, and aging. Plant-based individuals relying on ALA sources for their omega-3 intake are at high risk for insufficient EPA and DHA levels — vegan DHA/EPA from algae oil (the original source from which fish accumulate their omega-3) is the appropriate solution.
The Omega-3 Index: The Biomarker That Actually Matters
The omega-3 index — EPA+DHA as a percentage of total red blood cell membrane fatty acids — is the most clinically meaningful measure of omega-3 status. Unlike blood levels (which fluctuate with recent intake), the omega-3 index reflects tissue incorporation over the 3-4 month RBC lifespan, providing a time-integrated measure of long-term omega-3 adequacy analogous to HbA1c for glucose.
Harris and Von Schacky established the omega-3 index as a cardiovascular risk predictor in 2004: index below 4% (the US average is 4-5%) represents high cardiovascular risk; 4-8% is intermediate; above 8% is the target for cardiovascular protection. The OMEGA-REMODEL study and multiple cohort analyses have confirmed the index as an independent predictor of sudden cardiac death, total cardiovascular events, and cardiovascular mortality. The Framingham Heart Study data showed omega-3 index below 4% associated with 10-year cardiovascular event risk significantly higher than above-8% individuals.
Beyond cardiovascular risk, emerging research connects omega-3 index to: cognitive decline risk (studies by Tan 2012 from the Framingham cohort showed RBC omega-3 levels in the lowest quartile associated with smaller brain volume and lower cognitive test scores); depression (meta-analyses consistently show EPA is effective for major depression, particularly at doses above 1g/day EPA); preterm birth risk (omega-3 supplementation in pregnancy significantly reduces preterm birth in omega-3-deficient women — ORIP trial, n=5,544); and all-cause mortality in multiple large cohorts.
Testing: the omega-3 index is available through OmegaQuant Analytics (the research-standard lab), Cleveland HeartLab, and LabCorp. It can be ordered as a standalone test or included in comprehensive cardiovascular risk panels. At-home finger-stick test kits are available from OmegaQuant for approximately $50-60. This test should be part of every adult’s cardiovascular and metabolic health baseline.
The REDUCE-IT Trial and High-Dose EPA
The REDUCE-IT trial (Reduction of Cardiovascular Events with Icosapentaenoic Acid–Intervention Trial, n=8,179, Bhatt 2019 NEJM) demonstrated that 4g/day of icosapent ethyl (purified EPA ethyl ester, Vascepa) reduced major adverse cardiovascular events (MACE) by 25% compared to placebo on top of statin therapy in patients with elevated triglycerides (135-499 mg/dL) and established cardiovascular disease or diabetes. Cardiovascular death was reduced by 20%, total mortality by 13%, and myocardial infarction by 31%.
These results were striking — a 25% relative risk reduction is a larger cardiovascular benefit than adding a second statin or adding ezetimibe. The results prompted FDA approval of icosapent ethyl (Vascepa) for the specific indication of reducing cardiovascular events in high-risk patients on statins with elevated triglycerides. The mechanism debate continues: EPA reduced triglycerides by 20% in REDUCE-IT, but the cardiovascular benefit far exceeded what could be explained by triglyceride reduction alone. Proposed mechanisms include stabilization of atherosclerotic plaque membranes (EPA is incorporated into plaque and reduces plaque vulnerability), reduced platelet aggregation, improved endothelial function, and anti-arrhythmic effects on cardiac ion channels.
An important nuance: the STRENGTH trial (n=13,086) testing a different omega-3 formulation (EPA+DHA combined, corn oil control) did not show cardiovascular benefit. The difference between REDUCE-IT (significant benefit) and STRENGTH (neutral) may relate to: EPA vs. EPA+DHA (DHA may counteract some of EPA’s benefits), different control oils (mineral oil in REDUCE-IT may have slightly increased cardiovascular risk in controls), or different patient populations. The preponderance of evidence supports EPA-dominant formulations for cardiovascular risk reduction in high-risk patients with elevated triglycerides.
Omega-3 for Depression and Mental Health
The evidence for omega-3 in depression is now substantial. Lin 2007 meta-analysis (Biological Psychiatry, 9 trials) demonstrated that EPA-dominant formulations (above 60% EPA of total EPA+DHA) significantly reduced depressive symptoms versus placebo; DHA-dominant formulations showed no significant effect. Mocking 2016 meta-analysis (Translational Psychiatry, 13 RCTs, n=1,233) confirmed that EPA is effective for depression, particularly for patients with clinical (not subclinical) depression, and that EPA above 1g/day produced the strongest effects.
The mechanism involves multiple pathways: EPA reduces neuroinflammation (elevated IL-6, IL-1β, and CRP are consistent features of major depression, and EPA reduces all three); EPA improves serotonin receptor density and function (DHA modulates membrane fluidity that affects serotonin transporter activity); and EPA-derived resolvins reduce hypothalamic neuroinflammation associated with HPA axis dysregulation that drives both depression and cortisol abnormalities. The omega-3 index correlates with depressive symptom severity in population studies — low omega-3 status is a risk factor for depression, and supplementation to correct deficiency reduces depressive symptoms.
For clinical depression, the evidence-based omega-3 protocol: EPA-dominant fish oil at 1-2g EPA/day minimum (equivalent to approximately 2-4 capsules of a high-EPA product or a concentrated EPA liquid), in addition to (not instead of) antidepressant therapy when indicated. The Lyoo 2012 Korean RCT demonstrated creatine plus SSRI was significantly more effective than SSRI alone — and EPA produces similar adjunctive benefits through complementary mechanisms.
Formulations: Not All Fish Oil Is Equal
The omega-3 supplement market is rife with products that appear identical but vary dramatically in actual EPA+DHA content and bioavailability. Understanding formulation is essential for achieving therapeutic doses without excessive capsule consumption.
Ethyl ester (EE) fish oil: The most common form in standard supplements (Nordic Naturals Ultimate Omega EE, many pharmacy brands). EPA and DHA are esterified with ethanol rather than bound to glycerol. Bioavailability is lower than triglyceride forms unless taken with a high-fat meal — fat is required to stimulate bile and lipase activity for proper absorption. The advantage: very high EPA+DHA concentration possible (up to 90% EPA+DHA in concentrated forms). Vascepa (icosapent ethyl) is a pharmaceutical EE form taken with food specifically to maximize bioavailability.
Re-esterified triglyceride (rTG) fish oil: EPA and DHA are attached to a glycerol backbone mimicking natural fish triglycerides. Bioavailability is 70% higher than EE form in fasted state and approximately equal in fed state. This is considered the premium form for supplementation: Carlson Maximum Omega 2000, Nordic Naturals ProOmega 2000 (the rTG version), and Thorne Super EPA are rTG products. More expensive per mg of EPA+DHA than EE.
Phospholipid form (krill oil): EPA and DHA in krill oil are bound to phospholipids rather than triglycerides. Bioavailability may be superior in some studies (phospholipids are directly incorporated into cell membranes without re-esterification); however, krill oil provides far less total EPA+DHA per capsule (typically 100-200mg vs. 500-1,000mg for fish oil). For therapeutic doses of 2-4g EPA+DHA, krill oil capsules at standard doses are impractical and extremely expensive. Krill oil is reasonable for maintenance dosing at lower levels but not for therapeutic anti-inflammatory or cardiovascular applications.
Algae-derived DHA/EPA: The primary option for vegans and those avoiding fish. Algae is the original source of marine omega-3 — fish accumulate EPA and DHA by consuming algae. Algae oil provides DHA-dominant omega-3 (typically 500-1,000mg DHA, less EPA). For vegetarians and vegans, supplementing with algae oil is strongly recommended. Newer algae oil formulations provide more balanced EPA+DHA ratios that are increasingly available (Ovega-3 DHA+EPA, Testa Omega-3).
Oxidation and rancidity: Fish oil is highly susceptible to oxidation, which both reduces efficacy and produces pro-inflammatory aldehydes from lipid peroxidation. Oxidized fish oil may be worse than no fish oil. Quality indicators: TOTOX (total oxidation value) below 10; peroxide value below 5 meq/kg; anisidine value below 20. Reputable brands test and publish these values (IFOS certification). Consumer protection: fish oil should smell mildly of fish, not rancid or paintlike. Refrigerate after opening. Discard products that smell strongly rancid. Enteric coating does not protect against oxidation and merely disguises rancid taste.
Therapeutic Dosing by Indication
Standard fish oil dosing recommendations (typically 1g “fish oil” per day on supplement labels) are grossly inadequate for most therapeutic applications. The effective doses from clinical trials by indication:
General anti-inflammatory and cardiovascular prevention: 2-3g EPA+DHA/day. This requires approximately 4-6 standard fish oil capsules (typical 1,000mg capsule with 300mg EPA+DHA) or 2-3 capsules of concentrated omega-3 (1,000mg EPA+DHA per capsule).
Hypertriglyceridemia: 3-4g EPA+DHA/day. Omega-3 is FDA-approved for very high triglycerides (above 500 mg/dL) at prescription doses (Vascepa 4g/day, Lovaza 4g/day). For triglycerides of 200-500 mg/dL, 2-3g/day reduces triglycerides 20-35%.
Depression: Minimum 1g EPA/day (EPA-dominant product). Studies used 1-2g EPA with some suggesting higher doses for more severe depression. Use EPA-dominant product (above 60% of total omega-3 as EPA).
Rheumatoid arthritis: 3-4g EPA+DHA/day — at this dose, multiple RCTs show reduced joint swelling, morning stiffness, and NSAID requirement. Effects require 12-16 weeks to reach maximum benefit.
Pregnancy: 600-1,000mg DHA/day minimum during pregnancy and lactation; studies supporting reduction in preterm birth used 800-1,000mg DHA + 100-200mg EPA. The ORIP trial benefit was concentrated in women with low baseline omega-3 index below 5%.
Cognitive preservation and neuroprotection: 1-2g DHA/day for brain-targeted supplementation. Studies show DHA supplementation preserves hippocampal volume and improves memory performance in mild cognitive impairment.
Frequently Asked Questions
How much omega-3 should I take per day?
The answer depends on your current omega-3 index and clinical goal. For general cardiovascular and anti-inflammatory prevention: 2-3g EPA+DHA/day (not total fish oil — read the label for actual EPA+DHA content per serving). For elevated triglycerides: 3-4g EPA+DHA/day. For depression: minimum 1g EPA/day from an EPA-dominant product. For a known low omega-3 index below 4%: start with 3-4g EPA+DHA/day and retest at 3 months. The only way to know if your dose is achieving your target index is to test — most people need more omega-3 than they think.
What is the best fish oil supplement?
The best fish oil is IFOS-certified, in re-esterified triglyceride (rTG) form for maximum absorption, with published TOTOX values below 10, and with high EPA+DHA content per capsule to minimize capsule burden. Well-regarded brands meeting these criteria include Nordic Naturals ProOmega 2000 (rTG), Carlson Super Omega-3 (rTG), Thorne Super EPA (EE with high concentration), and Metagenics OmegaGenics EPA-DHA 2400. For prescription-grade omega-3, Vascepa (icosapent ethyl, EPA-only) and Lovaza (EPA+DHA) are FDA-approved pharmaceutical formulations with pharmaceutical-grade purity and TOTOX specifications.
Can omega-3 cause bleeding problems?
At therapeutic doses of 2-4g EPA+DHA/day, omega-3 has antiplatelet effects — it reduces platelet aggregation. In clinical trials, this has not translated to clinically significant bleeding at doses up to 4g/day. The REDUCE-IT trial at 4g/day did not show increased serious bleeding events versus placebo. However, individuals taking anticoagulants (warfarin, direct oral anticoagulants like apixaban or rivaroxaban) should discuss omega-3 supplementation with their prescribing physician, as the combination may mildly prolong bleeding time. Pre-surgical discontinuation of omega-3 for 5-7 days before elective procedures is commonly recommended as a conservative precaution, though the evidence that this is necessary is weak.
Is fish oil the same as omega-3?
“Omega-3” refers to a family of fatty acids including ALA (plant-based), EPA, and DHA. “Fish oil” contains EPA and DHA in varying concentrations — a standard 1,000mg fish oil capsule typically contains only 180mg EPA and 120mg DHA (300mg total). “Omega-3 fish oil” on labels can be misleading — always check the Supplement Facts panel for actual EPA and DHA content per serving. For therapeutic anti-inflammatory and cardiovascular applications, what matters is the EPA+DHA dose, not the total fish oil dose. A concentrated 1,200mg EPA+DHA product provides 4× the active omega-3 of a standard 300mg product at the same capsule count.
Omega-3 fatty acids are the most evidence-supported anti-inflammatory nutritional intervention available — 3,000+ clinical trials across cardiovascular risk, inflammation, depression, cognitive health, and autoimmune conditions confirm their benefit when dosed appropriately. If you would like omega-3 index testing and a personalized EPA+DHA protocol based on your cardiovascular risk, inflammatory markers, and specific health goals, Dr. Tom Biernacki and The Private Practice offer comprehensive functional medicine evaluations. Call (810) 206-1402 to schedule your consultation and get your omega-3 status measured and optimized.